shutterstock_diy13

Shutterstock.com / diy13

21 June 2022Big PharmaAzadeh Vahdat

Gilenya injunction bid: big pharma takeaways

Swiss drug-maker, Novartis, sought a preliminary injunction to keep Teva and four other generics off the market for its prescription-only relapse remitting multiple sclerosis treatment, fingolimod, sold under the brand name, Gilenya.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big pharma steps up access, but uneven progress made: report

16 November 2022 Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.

Fed Circuit reverses Novartis’ drug patent win

23 June 2022 The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.

More on this story

Big pharma steps up access, but uneven progress made: report

16 November 2022 Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.

Fed Circuit reverses Novartis’ drug patent win

23 June 2022 The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.

More on this story

Big pharma steps up access, but uneven progress made: report

16 November 2022 Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.

Fed Circuit reverses Novartis’ drug patent win

23 June 2022 The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.

More features

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant

Mental health IP toolkit: Diversity Champ’s stress-busting tips

Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

Patent cliff: 5 blockbusters running out of road

‘Always new twists’: Bayer legal team on defending a $4bn drug

Novartis and MSN feud intensifies after Fed Circ denies rehearing

EU court signals tough stance on ‘pay-for-delay’ pharma deals

Interpreting the SPC manufacturing waiver: EU courts diverge